Please login to the form below
ESMO
This page shows the latest ESMO news and features for those working in and with pharma, biotech and healthcare.
Merck closes in on adjuvant melanoma indication for Keytruda
At last year’s European Society for Medical Oncology (ESMO) congress, Bristol-Myers Squibb’s Opdivo (nivolumab) was found to be more effective than Yervoy (ipilimumab) - BMS’CTLA4 inhibitor which is
Latest news
-
Roche buys cancer company Ignyta for $1.7bn
It has breakthrough status from the FDA. Interim data from that study - reported at the European Society of Medical Oncology (ESMO) conference in September - showed that entrectinib achieved a response rate ... Entrectinib isn’t the only drug in
-
Data backs up Roche’s Tecentriq/Avastin combo in lung cancer
The data is being presented today at the European Society for Medical Oncology (ESMO) cancer immunotherapy congress in Geneva.
-
BMS adds another EU indication to Opdivo’s growing list
Researchers found Opdivo met its primary endpoint of recurrence-free survival and results were presented at the 2017’s European Society for Medical Oncology (ESMO) based in Madrid, Spain and simultaneously
-
Novartis scores but Roche misses in melanoma trials
The two studies reported at the European Society of Clinical Oncology (ESMO) congress in Madrid this week were carried out in high-risk, early-stage patients with stage III BRAF ... Both ipilimumab and the combination of dabrafenib plus trametinib have
-
Lilly's abemaciclib data leaves potential uncertain
The MONARCH 3 trial was reported at the European Society of Medical Oncology (ESMO) conference in Madrid over the weekend, and showed that the CDK4/6 inhibitor prolonged progression-free survival
More from news
Approximately 9 fully matching, plus 20 partially matching documents found.
Latest Intelligence
-
Biologic or biosimilar: what are prescribers thinking?
independent organisations such as ESMO, which recently published a paper supporting biosimilars as an option for sustainable cancer treatment.
-
Accelerating innovation
Phase II results from its CABOSUN trial, in which it was compared with Sutent in previously untreated advanced RCC, were released at this year’s European Society for Medical Oncology (ESMO) ... As the ESMO meeting began, Ipsen received the news that
-
Charting a course for expansion
When I met him at the annual European Society for Medical Oncology (ESMO) meeting in Copenhagen last month he explained how international expansion and oncology were key to Ipsen's plans. ... In Copenhagen, Ipsen's ESMO focus was on the CABOSUN study,
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Why patient education is important in oncology
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
-
FALCON trial of fulvestrant for advanced breast cancer
FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. Summary/transcript. Prof. Matthew Ellis from the Baylor College of Medicine
-
How pembrolizumab will change the management of advanced lung cancer
How pembrolizumab will change the management of advanced lung cancer. The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
Dr Choueiri, who presented the results at ESMO 2016, explains, they also had an early look at overall survival (OS), which is not significant yet but trending in the right direction.
-
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
We talked to Dr Ursula Matulonis of the Dana-Farber Cancer Institute, who co-authored the abstract presented at ESMO.
More from PMHub
Approximately 8 fully matching, plus 0 partially matching documents found.
Featured jobs
- Account Director or Senior Account Director
-
Salary TBC
-
Account Manager
-
Negotiable
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Senior Medical Writer
-
Salary is DOE
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Sudler London - Senior Medical Writer
-
Competitive
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Systematic Review Lead- London
-
Negotiable
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Sudler London - Account Director
-
Competitive
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
Subscribe to our email news alerts
- Moving annual total (MAT)
- Key success factor (KSF)
- AZ prepares to file COPD triple, taking on rival GSK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Gilead targets hep B in half a billion dollar deal with Precision BioSciences
- Teva wins FDA OK for crucial migraine drug
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Apex.co.uk Conferences, Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
